Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31385878 | 0.85 | CA12 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7023132 | 0.83 | NR1H2 (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19638080 | 0.80 | GPR119 (0.38) | ESR2ALDH1A1MAPTTDP1MEN1 | |
| SCHEMBL7824855 | 0.78 | CRHBP (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18190298 | 0.78 | L3MBTL1 (0.36) | L3MBTL1CRHBPCRHR2MEN1KMT2A | |
| SCHEMBL11911366 | 0.76 | GPR119 (0.39) | ESR2L3MBTL1LMNAALDH1A1MAPT | |
| SCHEMBL21416268 | 0.76 | CA12 (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18608207 | 0.74 | CA1 (0.63) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31566784 | 0.73 | L3MBTL1 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12272048 | 0.73 | TBXAS1 (0.40) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3248980-B1 | JAK INHIBITOR | WUXI FORTUNE PHARMACEUTICAL CO LTD (CN) | 2023-09-06 | — | — | EP | disclosed |
| CN-108349977-B | JAK inhibitors | 无锡福祈制药有限公司 | 2021-05-25 | — | — | CN | disclosed |
| US-10617690-B2 | JAK inhibitor | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2020-04-14 | — | — | US | disclosed |
| US-20170360794-A1 | JAK INHIBITOR | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2017-12-21 | — | — | US | disclosed |
| EP-3248980-A1 | JAK INHIBITOR | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2017-11-29 | — | — | EP | disclosed |
| CN-1468241-A | Heterocyclic compounds as ligands of the gabaa receptor | — | 2004-01-14 | — | — | CN | disclosed |
| EP-1325006-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABA A? RECEPTOR | NEUROGEN CORPORATION (US) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002012442-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABAA RECEPTOR | NEUROGEN CORPORATION (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360794-A1 | JAK INHIBITOR | JAK2, JAK1, JAK3 | CA12 4572/4885CA1 4783/4885CA2 3472/4885 |
| US-10617690-B2 | JAK inhibitor | JAK2, JAK1, JAK3 | CA12 4572/4885CA1 4783/4885CA2 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.